Julie Brown - Smith Nephew CFO, Director and Member of Disclosures Committee
| SNNUF Stock | USD 11.93 0.14 1.16% |
Director
Ms. Julie Brown is no longer Chief Financial Officer Executive Director of Smith Nephew PLC. effective January 31 2017. She is a graduate Chartered Accountant and Fellow of the Institute of Taxation. She trained with KPMG before working at AstraZeneca PLC where she served as Vice President Group Finance and ultimately as Interim Chief Financial Officer. Prior to that she was Regional Vice President Latin America Marketing Company President AstraZeneca Portugal and Vice President Corporationrationrate Strategy and RD Chief Financial Officer. In both Julies country and regional roles trading margins increased significantly improving the efficiency and profitability of the business. Her experience encompasses many areas of the healthcare value chain including Commercial Operations RD and Business Development. She has led multibillion dollar cost saving and restructuring programmes in Operations RD and the Commercial organisations and led major refinancing programmes including the issuance of 2 billion US bonds. Julie has so far in her career fulfilled two Nonexecutive Directorships with the NHS in the UK and the Board of the British Embassy. since 2013.
| Age | 52 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Michael Berman | InspireMD | 57 | |
| James Loughlin | InspireMD | 71 | |
| Paul Stuka | InspireMD | 60 | |
| James Barry | InspireMD | 57 | |
| Campbell Rogers | InspireMD | 53 | |
| Thomas Kester | InspireMD | 68 | |
Management Performance
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namal Nawana, CEO, Executive Director | ||
| Michael Friedman, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Director | ||
| Deepak Nath, CEO Director | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Director | ||
| AnneFrancoise Nesmes, CFO Director | ||
| Helen Barraclough, Company Counsel | ||
| Rodrigo Bianchi, President IRAMEA | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, Sports Orthopaedics | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Non-Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Director | ||
| Simon Fraser, President - Advanced Wound Management | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, CFO, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, VP Communications | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Robin Freestone, Non-Executive Director | ||
| Paul Connolly, Pres Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Director | ||
| Mark Gladwell, President - Global Operations | ||
| Andrew Swift, VP Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President Europe and Canada | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 14.08 B | |||
| Shares Outstanding | 873.35 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 52.60 % | |||
| Price To Earning | 23.41 X | |||
| Price To Book | 2.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |